NCT04615065 Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
| NCT ID | NCT04615065 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Groningen |
| Condition | Acute Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 35,000 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2030-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35,000 participants in total. It began in 2020-09-01 with a primary completion date of 2030-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named "Acutelines". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.
Eligibility Criteria
Inclusion Criteria, at least one of the following: * Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system; * Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS; * Shock * Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria) * Acute kidney injury (AKI) * Anaphylactic reaction * Syncope * Intoxication * Thrombosis * Pulmonary embolism * Bleeding while using anti-coagulant drugs * Gastro-intestinal bleeding * Electrolyte disturbance Exclusion Criteria: * Referred for organ transplantation as recipient * Transfer from other hospital * Accidental contact patient material (i.e. internal work-related accident) While data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \[red or orange\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.
Contact & Investigator
Ewoud ter Avest, MD, PhD
STUDY CHAIR
University Medical Center Groningen
Frequently Asked Questions
Who can join the NCT04615065 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04615065 currently recruiting?
Yes, NCT04615065 is actively recruiting participants. Contact the research team at acutelines@umcg.nl for enrollment information.
Where is the NCT04615065 trial being conducted?
This trial is being conducted at Groningen, Netherlands.
Who is sponsoring the NCT04615065 clinical trial?
NCT04615065 is sponsored by University Medical Center Groningen. The principal investigator is Ewoud ter Avest, MD, PhD at University Medical Center Groningen. The trial plans to enroll 35,000 participants.